瞬时无波形比值与血流储备分数指导经皮冠状动脉介入治疗
DEFINE-FLAIR试验将2492例冠心病患者按1:1随机分配至iFR指导或FFR指导的血运重建。主要终点为1年主要不良心脏事件(全因死亡、非致死性心肌梗死或计划外血运重建的复合终点)。1年时iFR组事件率为6.8%(78/1148),FFR组为7.0%(83/1182),风险差-0.2个百分点(95%CI -2.3至1.8),非劣效性P<0.001,风险比0.95(95%CI 0.68至1.33,P=0.78)。iFR组术中不良症状和体征发生率显著低于FFR组(3.1% vs 30.8%,P<0.001),中位手术时间更短(40.5分钟 vs 45.0分钟,P=0.001)。
要点
- iFR指导血运重建1年主要不良心脏事件风险不劣于FFR指导:iFR组6.8%(78/1148)vs FFR组7.0%(83/1182),风险差-0.2个百分点(95%CI -2.3至1.8),非劣效性P<0.001。
- iFR组术中不良症状和体征发生率显著低于FFR组:39例(3.1%)vs 385例(30.8%),P<0.001。
- iFR组中位手术时间显著短于FFR组:40.5分钟 vs 45.0分钟,P=0.001。
- 主要终点各组分及心血管或非心血管死亡风险在两组间无显著差异。
- iFR是不需腺苷给药的替代指标,本研究支持其用于指导冠心病血运重建。
适用人群与场景
- 冠状动脉疾病患者,共2492例,按1:1随机分配至iFR指导或FFR指导的血运重建组。
研究设计与关键结果
- 研究设计:随机对照试验,2492例冠状动脉疾病患者按1:1随机分配至iFR指导(1148例评估主要终点)或FFR指导(1182例评估主要终点)的血运重建。
- 主要终点:1年主要不良心脏事件(全因死亡、非致死性心肌梗死或计划外血运重建的复合终点),iFR组78/1148例(6.8%)vs FFR组83/1182例(7.0%),风险差-0.2个百分点(95%CI -2.3至1.8),非劣效性P<0.001,风险比0.95(95%CI 0.68至1.33,P=0.78)。
- 次要终点:主要终点各组分及心血管或非心血管死亡风险两组间无显著差异。
- 安全性:术中不良症状和体征iFR组39例(3.1%)vs FFR组385例(30.8%),P<0.001;中位手术时间iFR组40.5分钟 vs FFR组45.0分钟,P=0.001。
证据类型、等级与局限
- 证据类型:随机对照试验(DEFINE-FLAIR,ClinicalTrials.gov NCT02053038),由Philips Volcano资助。
- 非劣效性设计,非劣效界值为风险差3.4个百分点。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于冠状动脉疾病患者,iFR指导的血运重建在1年主要不良心脏事件风险上不劣于FFR指导,且术中不良症状和体征更少、手术时间更短,作者结论支持iFR作为不需腺苷给药的替代指标用于指导血运重建。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR.
METHODS: We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio, to undergo either iFR-guided or FFR-guided coronary revascularization. The primary end point was the 1-year risk of major adverse cardiac events, which were a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization. The trial was designed to show the noninferiority of iFR to FFR, with a margin of 3.4 percentage points for the difference in risk.
RESULTS: At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk, -0.2 percentage points; 95% confidence interval [CI], -2.3 to 1.8; P<0.001 for noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P=0.78). The risk of each component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the groups. The number of patients who had adverse procedural symptoms and clinical signs was significantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385 patients [30.8%], P<0.001), and the median procedural time was significantly shorter (40.5 minutes vs. 45.0 minutes, P=0.001).
CONCLUSIONS: Coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The rate of adverse procedural signs and symptoms was lower and the procedural time was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE-FLAIR ClinicalTrials.gov number, NCT02053038 .).
参考来源
- Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017. PMID: 28317458. doi:10.1056/NEJMoa1700445
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。